What's new

Human medicines European public assessment report (EPAR): Rivastigmine Actavis, rivastigmine, Date of authorisation: 16/06/2011, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Actavis, rivastigmine, Date of authorisation: 16/06/2011, Revision: 21, Status: Authorised

Jun 13, 2025 - 15:05
 0
Human medicines European public assessment report (EPAR): Rivastigmine Actavis, rivastigmine, Date of authorisation: 16/06/2011, Revision: 21, Status: Authorised
Human medicines European public assessment report (EPAR): Rivastigmine Actavis, rivastigmine, Date of authorisation: 16/06/2011, Revision: 21, Status: Authorised
Read More

Tags:

Previous Article

EMEA-002963-PIP01-21-M01

Next Article

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept...

Related Posts

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025  0

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 22 May 2025, 12:30 (CEST) to 22 May 2025, 17:30 (CEST)

Clinical Trials Information System (CTIS): Information ...

May 19, 2025  0

Human medicines European public assessment report (EPAR): Atropine sulfate FGK, atropine, Status: Opinion under re-examination

Human medicines European public assessment report (EPAR...

Jun 3, 2025  0